Referencias

English | Otros idiomas
Imprimir
PÁGINA 4 de 6

‹Ver Tabla de contenidos

Páginas relacionadas
  1. Cox NJ, Subbarao K. Influenza. Lancet. 1999 Oct 9;354(9186):1277-82.
  2. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51:407-21.
  3. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990 Mar;175(1):59-68.
  4. McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol. 2004 Dec;78(23):12817-28.
  5. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol. 2008 Jun;66(6):655-63.
  6. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18;360(25):2605-15.
  7. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009 Jul 10;325(5937):197-201.
  8. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979 Jan;35(1):69-75.
  9. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol. 1983;37:529-49.
  10. CDC. La temporada de influenza. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2015.  https://www.cdc.gov/flu/about/season/index.html
  11. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol. 1975 Jun;101(6):532-51.
  12. CDC. FluView-Vigilancia de enfermedades en pacientes ambulatorios. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE.UU., CDC,  2018. Disponible en www.cdc.gov/flu/weekly.
  13. Tokars JI, Olsen SJ, Reed C. The seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2017 Dec 1.
  14. Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. Vaccine. 2018 May 31;36(23):3199-207.
  15. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369.
  16. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses. 2018 Jan;12(1):132-7.
  17. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006 Jul 6;355(1):31-40.
  18. Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, et al. The burden of influenza in young children, 2004-2009. Pediatrics. 2013 Feb;131(2):207-16.
  19. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000 Jan 27;342(4):225-31.
  20. Jules A, Grijalva CG, Zhu Y, Talbot HK, Williams JV, Poehling KA, et al. Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011. Pediatrics. 2015 Jan;135(1):e66-74.
  21. Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006 Dec;118(6):2409-17.
  22. Coffin SE, Zaoutis TE, Rosenquist AB, Heydon K, Herrera G, Bridges CB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007 Apr;119(4):740-8.
  23. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 May;54(10):1427-36.
  24. Schrag SJ, Shay DK, Gershman K, Thomas A, Craig AS, Schaffner W, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect Dis J. 2006 May;25(5):395-400.
  25. Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004 Jun;113(6):1758-64.
  26. O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004 Mar;113(3 Pt 1):585-93.
  27. Miller EK, Griffin MR, Edwards KM, Weinberg GA, Szilagyi PG, Staat MA, et al. Influenza burden for children with asthma. Pediatrics. 2008 Jan;121(1):1-8.
  28. Neuzil KM, Wright PF, Mitchel EF, Jr., Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000 Dec;137(6):856-64.
  29. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86.
  30. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005 Dec 15;353(24):2559-67.
  31. FluView: Mortalidad infantil asociada a la influenza. Atlanta, GA: CDC; 2017. Disponible en: gis.cdc.gov/GRASP/Fluview/PedFluDeath.htm.
  32. Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008 Oct;122(4):805-11.
  33. D'Mello T, Brammer L, Blanton L, Kniss K, Smith S, Mustaquim D, et al. Update: Influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep. 2015 Mar 6;64(8):206-12.
  34. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-Associated Pediatric Deaths in the United States, 2010-2016. Pediatrics. 2018 Apr;141(4).
  35. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086-96.
  36. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med. 1997 May;39(5):408-14.
  37. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA. 2000 Oct 4;284(13):1655-63.
  38. Olsen GW, Burris JM, Burlew MM, Steinberg ME, Patz NV, Stoltzfus JA, et al. Absenteeism among employees who participated in a workplace influenza immunization program. J Occup Environ Med. 1998 Apr;40(4):311-6.
  39. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine. 2003 May 16;21(17-18):2207-17.
  40. Van Wormer JJ, King JP, Gajewski A, McLean HQ, Belongia EA. Influenza and Workplace Productivity Loss in Working Adults. J Occup Environ Med. 2017 Dec;59(12):1135-9.
  41. Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S75-82.
  42. CDC. Actualización: actividad de la influenza - Estados Unidos, temporada 2009-10. Informe Semanal de Morbilidad y Mortalidad (MMWR), 30 de julio del 2010;59(29):901-8.
  43. Epperson S, Blanton L, Kniss K, Mustaquim D, Steffens C, Wallis T, et al. Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep. 2014 Jun 6;63(22):483-90.
  44. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007 Jan 15;25(5):846-55.
  45. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-53.
  46. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis. 2012 Dec 1;206(11):1652-9.
  47. Blackburn RM, Zhao H, Pebody R, Hayward AC, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015. Clin Infect Dis. 2018 Jan 6.
  48. Boehme AK, Luna J, Kulick ER, Kamel H, Elkind MSV. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018 Apr;5(4):456-63.
  49. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005 Oct;33(10 Suppl):S390-7.
  50. Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ. 2007 Feb 13;176(4):463-8.
  51. Prasad N, Huang QS, Wood T, Aminisani N, McArthur C, Baker MG, et al. Influenza associated outcomes among pregnant, post-partum, and non-pregnant women of reproductive age. J Infect Dis. 2019 Jan 23.
  52. Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies. Vaccine. 2017 Jan 23;35(4):521-8.
  53. Harris J. Influenza occurring in pregnant women: A statistical study of thirteen hundred and fifty cases. . JAMA. 1919;72:978-80.
  54. Louie JK, Acosta M, Jamieson DJ, Honein MA, California Pandemic Working G. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010 Jan 7;362(1):27-35.
  55. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009 Aug 8;374(9688):451-8.
  56. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol. 1959 Dec;78:1172-5.
  57. CDC. Influenza pandémica A (H2009N1) 1 en mujeres embarazadas que requieren cuidados intensivos - Ciudad de Nueva York, 2009. Informe Semanal de Morbilidad y Mortalidad (MMWR), 26 de marzo del 2010;59(11):321-6.
  58. Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T, Schwarz AG, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol. 2010 Apr;115(4):717-26.
  59. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol. 2011 Jul;205(1):10-8.
  60. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014 Jun 5;370(23):2211-8.
  61. Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010 Apr 21;303(15):1517-25.
  62. Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. Hospitalizations with respiratory illness among pregnant women during influenza season. Obstet Gynecol. 2006 Jun;107(6):1315-22.
  63. Haberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med. 2013 Jan 24;368(4):333-40.
  64. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, Ukoss. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ. 2011 Jun 14;342:d3214.
  65. Regan AK, Moore HC, Sullivan SG, N DEK, Effler PV. Epidemiology of seasonal influenza infection in pregnant women and its impact on birth outcomes. Epidemiol Infect. 2017 Oct;145(14):2930-9.
  66. Irving WL, James DK, Stephenson T, Laing P, Jameson C, Oxford JS, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG. 2000 Oct;107(10):1282-9.
  67. Griffiths PD, Ronalds CJ, Heath RB. A prospective study of influenza infections during pregnancy. J Epidemiol Community Health. 1980 Jun;34(2):124-8.
  68. Hartert TV, Neuzil KM, Shintani AK, Mitchel EF, Jr., Snowden MS, Wood LB, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol. 2003 Dec;189(6):1705-12.
  69. Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006 Jul;76(7):507-16.
  70. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. Hum Reprod. 2014 Apr;29(4):809-23.
  71. Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology. 2005 Mar;16(2):216-9.
  72. Oster ME, Riehle-Colarusso T, Alverson CJ, Correa A. Associations between maternal fever and influenza and congenital heart defects. J Pediatr. 2011 Jun;158(6):990-5.
  73. Shahrukh Hashmi S, Gallaway MS, Waller DK, Langlois PH, Hecht JT, National Birth Defects Prevention S. Maternal fever during early pregnancy and the risk of oral clefts. Birth Defects Res A Clin Mol Teratol. 2010 Mar;88(3):186-94.
  74. Botto LD, Erickson JD, Mulinare J, Lynberg MC, Liu Y. Maternal fever, multivitamin use, and selected birth defects: evidence of interaction? Epidemiology. 2002 Jul;13(4):485-8.
  75. Burney LE. Influenza immunization: Statement. Public Health Rep. 1960 Oct;75(10):944.
  76. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62.
  77. Garg S, Jain S, Dawood FS, Jhung M, Perez A, D'Mello T, et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis. 2015 Aug 26;15:369.
  78. Dharan NJ, Sokolow LZ, Cheng PY, Gargiullo P, Gershman K, Lynfield R, et al. Child, household, and caregiver characteristics associated with hospitalization for influenza among children 6-59 months of age: an emerging infections program study. Pediatr Infect Dis J. 2014 Jun;33(6):e141-50.
  79. Gill PJ, Ashdown HF, Wang K, Heneghan C, Roberts NW, Harnden A, et al. Identification of children at risk of influenza-related complications in primary and ambulatory care: a systematic review and meta-analysis. Lancet Respir Med. 2015 Feb;3(2):139-49.
  80. Neuzil KM, Reed GW, Mitchel EF, Jr., Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999 Mar 10;281(10):901-7.
  81. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001 Feb 12;161(3):441-6.
  82. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis. 2011 Jan 15;52(2):219-27.
  83. Perez CM, Dominguez MI, Ceballos ME, Moreno C, Labarca JA, Rabagliati R, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS. 2010 Nov 27;24(18):2867-9.
  84. Riera M, Payeras A, Marcos MA, Viasus D, Farinas MC, Segura F, et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS. 2010 Oct 23;24(16):2461-7.
  85. Martinez E, Marcos MA, Hoyo-Ulloa I, Anton A, Sanchez M, Vilella A, et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 2011 Apr;12(4):236-45.
  86. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011. Emerg Infect Dis. 2013 Nov;19(11):1766-74.
  87. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged >/=5 years in a high HIV-prevalence setting, 2009-2012. PLoS One. 2015;10(2):e0117716.
  88. Cilloniz C, Garcia-Vidal C, Moreno A, Miro JM, Torres A. Community-acquired bacterial pneumonia in adult HIV-infected patients. Expert Rev Anti Infect Ther. 2018 Jul;16(7):579-88.
  89. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009 Nov 12;361(20):1935-44.
  90. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009 Nov 4;302(17):1872-9.
  91. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009 Nov 4;302(17):1896-902.
  92. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One. 2010 Mar 15;5(3):e9694.
  93. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis. 2011 Sep;53(5):413-21.
  94. Karki S, Muscatello DJ, Banks E, MacIntyre CR, McIntyre P, Liu B. Association between body mass index and laboratory-confirmed influenza in middle aged and older adults: a prospective cohort study. Int J Obes (Lond). 2018 Aug;42(8):1480-8.
  95. Coleman LA, Waring SC, Irving SA, Vandermause M, Shay DK, Belongia EA. Evaluation of obesity as an independent risk factor for medically attended laboratory-confirmed influenza. Influenza Other Respir Viruses. 2013 Mar;7(2):160-7.
  96. Moser JS, Galindo-Fraga A, Ortiz-Hernandez AA, Gu W, Hunsberger S, Galan-Herrera JF, et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir Viruses. 2019 Jan;13(1):3-9.
  97. Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009 Nov 12;361(20):1925-34.
  98. Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake D, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill. 2009 Aug 27;14(34).
  99. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M, et al. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill. 2009 Oct 22;14(42).
  100. CDC. Muertes relacionadas con la influenza pandémica A 2009 (H1N1) entre nativos de Alaska/tribus indígenas de Estados Unidos - 12 estados, 2009.  Informe Semanal de Morbilidad y Mortalidad (MMWR). 11 de diciembre del 2009;58(48):1341-4.
  101. Hutchins SS, Fiscella K, Levine RS, Ompad DC, McDonald M. Protection of racial/ethnic minority populations during an influenza pandemic. Am J Public Health. 2009 Oct;99 Suppl 2:S261-70.
  102. Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L, Kettner J, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ. 2010 Feb 23;182(3):257-64.
  103. Groom AV, Jim C, Laroque M, Mason C, McLaughlin J, Neel L, et al. Pandemic influenza preparedness and vulnerable populations in tribal communities. Am J Public Health. 2009 Oct;99 Suppl 2:S271-8.
  104. Hennessy TW, Bruden D, Castrodale L, Komatsu K, Erhart LM, Thompson D, et al. A case-control study of risk factors for death from 2009 pandemic influenza A(H1N1): is American Indian racial status an independent risk factor? Epidemiol Infect. 2016 Jan;144(2):315-24.
  105. Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine. 2006 Nov 10;24(44-46):6726-8.
  106. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006 Apr;35(2):337-44.
  107. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007 Oct;7(10):658-66.
  108. Talbot HK, Nian H, Chen Q, Zhu Y, Edwards KM, Griffin MR. Evaluating the case-positive, control test-negative study design for influenza vaccine effectiveness for the frailty bias. Vaccine. 2016 Apr 4;34(15):1806-9.
  109. Ferdinands JM, Shay DK. Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination. Clin Infect Dis. 2012 Jan 1;54(1):25-32.
  110. Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine. 2015 Mar 10;33(11):1313-6.
  111. Oxford JS, Schild GC, Potter CW, Jennings R. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. J Hyg (Lond). 1979 Feb;82(1):51-61.
  112. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001 Aug;20(8):733-40.
  113. Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 1997 Jun;15(9):962-7.
  114. La Montagne JR, Noble GR, Quinnan GV, Curlin GT, Blackwelder WC, Smith JI, et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis. 1983 Jul-Aug;5(4):723-36.
  115. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006 Dec;80(23):11756-66.
  116. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, et al. Antibody landscapes after influenza virus infection or vaccination. Science. 2014 Nov 21;346(6212):996-1000.
  117. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011 May 1;203(9):1309-15.
  118. King JC, Jr., Lichenstein R, Magder LS. Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012. Vaccine. 2013 Jan 21;31(5):839-44.
  119. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009 Jan 15;199(2):159-67.
  120. Dean AS, Moffatt CR, Rosewell A, Dwyer DE, Lindley RI, Booy R, et al. Incompletely matched influenza vaccine still provides protection in frail elderly. Vaccine. 2010 Jan 8;28(3):864-7.
  121. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respir Viruses. 2013 Sep;7(5):729-37.
  122. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.
  123. Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2019.
  124. Flublok Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2019.
  125. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017-18. J Infect Dis. 2018 Dec 18.
  126. Beran J, Peeters M, Dewe W, Raupachova J, Hobzova L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013 May 20;13:224.
  127. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013 Jun 15;207(12):1878-87.
  128. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J. 2014 Jun;33(6):630-6.
  129. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis. 2013 Jul 24;13:343.
  130. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013 Aug 15;208(4):544-53.
  131. Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013 Nov 12;31(47):5572-8.
  132. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewe W, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a phase III, randomized trial. Vaccine. 2014 Mar 14;32(13):1480-7.
  133. Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017 Apr 4;35(15):1856-64.
  134. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15;211(10):1529-40.
  135. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb;58(3):319-27.
  136. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010 Nov 1;51(9):997-1004.
  137. Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009 Dec 15;200(12):1861-9.
  138. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006 Oct 15;194(8):1032-9.
  139. Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr. 2006 Dec;149(6):755-62.
  140. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005 Jul;116(1):153-9.
  141. Eisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M, Shone LP, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics. 2008 Nov;122(5):911-9.
  142. Segaloff HE, Leventer-Roberts M, Riesel D, Malosh RE, Feldman BS, Shemer-Avni Y, et al. Influenza Vaccine Effectiveness Against Hospitalization in Fully and Partially Vaccinated Children in Israel; 2015-16, 2016-17, and 2017-18. Clin Infect Dis. 2019 Feb 11.
  143. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003 Sep 24;290(12):1608-16.
  144. Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018 May;2(5):338-49.
  145. Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, et al. Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season. Clin Infect Dis. 2018 Sep 11.
  146. Rolfes MA, Flannery B, Chung J, O'Halloran A, Garg S, Belongia EA, et al. Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season. Clin Infect Dis. 2019 Feb 2.
  147. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med. 1995 Oct;149(10):1113-7.
  148. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child. 1991 Apr;145(4):445-8.
  149. Norhayati MN, Ho JJ, Azman MY. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev. 2017 Oct 17;10:CD010089.
  150. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan;12(1):36-44.
  151. Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B, Zimmerman RK, et al. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. Clin Infect Dis. 2016 Feb 15;62(4):448-55.
  152. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006 Feb 20;24(8):1159-69.
  153. Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016 Jan 13;23(3):228-35.
  154. Gross PA, Weksler ME, Quinnan GV, Jr., Douglas RG, Jr., Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol. 1987 Sep;25(9):1763-5.
  155. Feery BJ, Cheyne IM, Hampson AW, Atkinson MI. Antibody response to one and two doses of influenza virus subunit vaccine. Med J Aust. 1976 Feb 14;1(7):186, 8-9.
  156. Levine M, Beattie BL, McLean DM. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ. 1987 Oct 15;137(8):722-6.
  157. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994 Dec 7;272(21):1661-5.
  158. Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018 Feb 1;2:CD004876.
  159. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis. 2014 Dec;14(12):1228-39.
  160. Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002 Aug 15;35(4):370-7.
  161. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994 Dec 15;121(12):947-52.
  162. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007 Oct 4;357(14):1373-81.
  163. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001 Sep 15;184(6):665-70.
  164. Chiu PJ, Chen CH, Chih YC. Effectiveness of the influenza vaccination program for the elderly in Taiwan. Vaccine. 2013 Jan 11;31(4):632-8.
  165. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017 Jul 27;22(30).
  166. Rondy M, El Omeiri N, Thompson MG, Leveque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017 Nov;75(5):381-94.
  167. Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006 Apr;35(2):345-52.
  168. Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med. 2012 Mar 26;172(6):484-91.
  169. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine. 2010 Oct 21;28(45):7267-72.
  170. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009 Sep 1;170(5):650-6.
  171. Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha R, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis. 2013 Sep;57(6):820-7.
  172. VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis. 2014 May 1;14:231.
  173. Arriola CS, Anderson EJ, Baumbach J, Bennett N, Bohm S, Hill M, et al. Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States. J Infect Dis. 2015 Oct 15;212(8):1200-8.
  174. Arriola C, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM, et al. Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza. Clin Infect Dis. 2017 Oct 15;65(8):1289-97.
  175. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001 Jul 15;154(2):155-60.
  176. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc. 1999 Feb;47(2):165-71.
  177. Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc. 1992 Jun;40(6):589-92.
  178. Libow LS, Neufeld RR, Olson E, Breuer B, Starer P. Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. J Am Geriatr Soc. 1996 Oct;44(10):1153-7.
  179. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993 Sep;168(3):647-56.
  180. Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J. 1987 Apr;6(4):398-403.
  181. Helmig RB, Maimburg RD, Erikstrup C, Nielsen HS, Petersen OB, Nielsen LP, et al. Antibody response to influenza A(H1N1)pdm09 in vaccinated, serologically infected and unaffected pregnant women and their newborns. Acta Obstet Gynecol Scand. 2015 Aug;94(8):833-9.
  182. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008 Oct 9;359(15):1555-64.
  183. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014 Sep 4;371(10):918-31.
  184. Tapia MD, Sow SO, Tamboura B, Teguete I, Pasetti MF, Kodio M, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis. 2016 Sep;16(9):1026-35.
  185. Steinhoff MC, Katz J, Englund JA, Khatry SK, Shrestha L, Kuypers J, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis. 2017 Sep;17(9):981-9.
  186. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis. 2010 Dec 15;51(12):1355-61.
  187. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med. 2011 Feb;165(2):104-11.
  188. Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S141-8.
  189. Thompson MG, Li DK, Shifflett P, Sokolow LZ, Ferber JR, Kurosky S, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis. 2014 Feb;58(4):449-57.
  190. Thompson MG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, et al. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016. Clin Infect Dis. 2018 Oct 11.
  191. Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, et al. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 Dec 18;36(52):8047-53.
  192. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA. 1994 Oct 12;272(14):1122-6.
  193. Kramarz P, Destefano F, Gargiullo PM, Chen RT, Lieu TA, Davis RL, et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr. 2001 Mar;138(3):306-10.
  194. Ong BA, Forester J, Fallot A. Does influenza vaccination improve pediatric asthma outcomes? J Asthma. 2009 Jun;46(5):477-80.
  195. Jaiwong C, Ngamphaiboon J. Effects of inactivated influenza vaccine on respiratory illnesses and asthma-related events in children with mild persistent asthma in Asia. Asian Pac J Allergy Immunol. 2015 Mar;33(1):3-7.
  196. Bueving HJ, Bernsen RM, de Jongste JC, van Suijlekom-Smit LW, Rimmelzwaan GF, Osterhaus AD, et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2004 Feb 15;169(4):488-93.
  197. Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch Dis Child. 2004 Aug;89(8):734-5.
  198. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax. 2003 Oct;58(10):835-9.
  199. American Lung Association. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001 Nov 22;345(21):1529-36.
  200. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013 Feb 28(2):CD000364.
  201. Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics. 1996 Aug;98(2 Pt 1):196-200.
  202. Mulpuru S, Li L, Ye L, Hatchette T, Andrew MK, Ambrose A, et al. Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest. 2019 Jan;155(1):69-78.
  203. Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009 Jul;64(7):567-72.
  204. Vila-Corcoles A, Ochoa O, de Diego C, Valdivieso A, Herreros I, Bobe F, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic pulmonary disease. Int J Clin Pract. 2008 Jan;62(1):10-7.
  205. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004 Dec 16;351(25):2611-8.
  206. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 May 7;105(18):2143-7.
  207. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004 Jan;25(1):25-31.
  208. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008 Jun;29(11):1350-8.
  209. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul;32(14):1730-5.
  210. Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. Vaccine. 2013 Oct 25;31(45):5168-77.
  211. Chiang MH, Wu HH, Shih CJ, Chen YT, Kuo SC, Chen TL. Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. Am Heart J. 2017 Nov;193:1-7.
  212. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis. 2016 Apr 15;213(8):1224-8.
  213. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis. 2016 Apr 15;213(8):1216-23.
  214. McLean HQ, Chow BD, VanWormer JJ, King JP, Belongia EA. Effect of Statin Use on Influenza Vaccine Effectiveness. J Infect Dis. 2016 Oct 15;214(8):1150-8.
  215. Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, et al. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis. 2018 Oct 27.
  216. Furth SL, Neu AM, McColley SA, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol. 1995 Oct;9(5):566-8.
  217. Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009 Jul;54(1):77-85.
  218. Antonen JA, Hannula PM, Pyhala R, Saha HH, Ala-Houhala IO, Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000 Sep;86(1):56-61.
  219. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med. 2014 Dec 19;12:244.
  220. Sayyad B, Alavian SM, Najafi F, Mokhtari Azad T, Ari Tabarestani MH, Shirvani M, et al. Efficacy of influenza vaccination in patients with cirrhosis and inactive carriers of hepatitis B virus infection. Iran Red Crescent Med J. 2012 Oct;14(10):623-30.
  221. Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine. 2002 Dec 20;20 Suppl 5:B33-5.
  222. Gaeta GB, Pariani E, Amendola A, Brancaccio G, Cuomo G, Stornaiuolo G, et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine. 2009 May 26;27(25-26):3373-5.
  223. Song JY, Cheong HJ, Ha SH, Hwang IS, Kee SY, Jeong HW, et al. Clinical impact of influenza immunization in patients with liver cirrhosis. J Clin Virol. 2007 Jul;39(3):159-63.
  224. Su FH, Huang YL, Sung FC, Su CT, Hsu WH, Chang SN, et al. Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection: A population-based analysis. Vaccine. 2016 Jan 2;34(1):120-7.
  225. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015 Mar 17;13:53.
  226. Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax. 2013 Jul;68(7):658-63.
  227. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol. 2012 Mar;119(3):631-9.
  228. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond). 2012 Aug;36(8):1072-7.
  229. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine. 2012 Jun 6;30(26):3937-43.
  230. Smit MA, Wang HL, Kim E, Barragan N, Aldrovandi GM, El Amin AN, et al. Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children. Pediatr Infect Dis J. 2016 Apr;35(4):440-5.
  231. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001 Sep-Oct;19(5):589-94.
  232. Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol. 1993 Oct;20(10):1769-73.
  233. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007 Jul;5(7):851-6.
  234. deBruyn JC, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012 Jan;18(1):25-33.
  235. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb;104(2):444-53.
  236. Shirai S, Hara M, Sakata Y, Tsuruoka N, Yamamoto K, Shimoda R, et al. Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy. Inflamm Bowel Dis. 2018 Apr 23;24(5):1082-91.
  237. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007 Apr;46(4):608-11.
  238. Lakota K, Perdan-Pirkmajer K, Sodin-Semrl S, Cucnik S, Subelj V, Prosenc K, et al. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study. Clin Rheumatol. 2019 Feb 14.
  239. Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther. 2011;13(6):R209.
  240. Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol. 2018 Jun;45(6):733-44.
  241. deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, et al. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis. 2016 Mar;22(3):638-47.
  242. Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun;77(6):898-904.
  243. Kotecha RS, Wadia UD, Jacoby P, Ryan AL, Blyth CC, Keil AD, et al. Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med. 2016 Feb;5(2):285-93.
  244. Ottoffy G, Horvath P, Muth L, Solyom A, Garami M, Kovacs G, et al. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. Pediatr Blood Cancer. 2014 Jun;61(6):1013-6.
  245. Kersun LS, Reilly A, Coffin SE, Boyer J, Luning Prak ET, McDonald K, et al. A prospective study of chemotherapy immunologic effects and predictors of humoral influenza vaccine responses in a pediatric oncology cohort. Influenza Other Respir Viruses. 2013 Nov;7(6):1158-67.
  246. Bektas O, Karadeniz C, Oguz A, Berberoglu S, Yilmaz N, Citak C. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors. Pediatr Blood Cancer. 2007 Dec;49(7):914-7.
  247. Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara K, Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer. 2005 Nov;45(6):831-7.
  248. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch Dis Child. 2001 Jun;84(6):496-500.
  249. Reilly A, Kersun LS, McDonald K, Weinberg A, Jawad AF, Sullivan KE. The efficacy of influenza vaccination in a pediatric oncology population. J Pediatr Hematol Oncol. 2010 Jul;32(5):e177-81.
  250. Choi DK, Fuleihan RL, Walterhouse DO. Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer. 2016 Nov;63(11):2011-8.
  251. Sykes A, Gerhardt E, Tang L, Adderson EE. The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia. J Pediatr. 2017 Dec;191:218-24 e1.
  252. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005 Nov;3(4):214-20.
  253. Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol. 2014;8:57-64.
  254. Natori Y, Humar A, Lipton J, Kim DD, Ashton P, Hoschler K, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017 Jul;52(7):1016-21.
  255. Halasa NB, Savani BN, Asokan I, Kassim A, Simons R, Summers C, et al. Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. Biol Blood Marrow Transplant. 2016 Mar;22(3):528-35.
  256. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995 Dec 1;182(6):1727-37.
  257. Huang KL, Ruben FL, Rinaldo CR, Jr., Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA. 1987 Apr 17;257(15):2047-50.
  258. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000 Jul 1;18(26):3040-9.
  259. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989 Aug 11;262(6):779-83.
  260. McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013 Jan 1;158(1):19-26.
  261. Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM, et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016 Jun 8;34(27):3141-8.
  262. Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, Wong SJ, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001 Jun 15;32(12):1784-91.
  263. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 1;52(1):128-37.
  264. Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS. 2013 Jan 28;27(3):369-79.
  265. Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, Ison MG, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011 Oct;11(10):2020-30.
  266. Mack DR, Chartrand SA, Ruby EI, Antonson DL, Shaw BW, Jr., Heffron TG. Influenza vaccination following liver transplantation in children. Liver Transpl Surg. 1996 Nov;2(6):431-7.
  267. Edvardsson VO, Flynn JT, Deforest A, Kaiser BA, Schulman SL, Bradley A, et al. Effective immunization against influenza in pediatric renal transplant recipients. Clin Transplant. 1996 Dec;10(6 Pt 1):556-60.
  268. Nailescu C, Xu X, Zhou H, Hall H, Wilson AC, Leiser JD, et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol. 2011 Mar;26(3):459-67.
  269. Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009 Jul;54(1):112-21.
  270. Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus AD, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant. 2008 Feb;8(2):332-7.
  271. Krairittichai U, Chittaganpitch M. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers. J Med Assoc Thai. 2013 Mar;96 Suppl 3:S1-7.
  272. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011 May;6(5):1192-7.
  273. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol. 2000 May;61(1):85-93.
  274. Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant. 2004 Nov;4(11):1805-9.
  275. Dengler TJ, Strnad N, Buhring I, Zimmermann R, Girgsdies O, Kubler WE, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation. 1998 Nov 27;66(10):1340-7.
  276. Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A, et al. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clin Infect Dis. 2017 Apr 1;64(7):829-38.
  277. Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, et al. A Double Blind Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Adult Solid Organ Transplant Recipients. Clin Infect Dis. 2017 Dec 14.
  278. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Apr 11;297(14):1577-82.
  279. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13;29(44):7733-9.
  280. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011 Mar 9;29(12):2272-8.
  281. Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11;28(2):379-85.
  282. Summary Basis for Regulatory Action: Flublok Quadrivalent. U.S. Department of Health and Human Services, Food and Drug Administration; 2016.
  283. Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. N Engl J Med. 2017 Jun 22;376(25):2427-36.
  284. Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age. J Infect Dis. 2017 Dec 5;216(10):1219-26.
  285. King JC, Jr., Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine. 2009 Nov 5;27(47):6589-94.
  286. Fluzone High-Dose [Package Insert]. Swiftwater, PA: Sanofi Pasetur; 2019.
  287. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007 Nov 1;25(44):7656-63.
  288. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009 Jul 15;200(2):172-80.
  289. Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22;166(10):1121-7.
  290. Clinical review:: Fluzone High-Dose. Silver Spring, MD: US Food and Drug Administration; 2014.
  291. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45.
  292. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015 Sep 11;33(38):4988-93.
  293. Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. Lancet Infect Dis. 2015 Dec;15(12):1459-66.
  294. Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017 Sep;5(9):738-46.
  295. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR, Centers for Disease C, Prevention Epicenter P. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015 Jul 15;61(2):171-6.
  296. Young-Xu Y, Van Aalst R, Mahmud SM, Rothman KJ, Thornton Snider J, Westreich D, et al. Relative Vaccine Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among Veterans Health Administration Patients. J Infect Dis. 2018 Feb 14.
  297. Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015 Mar;15(3):293-300.
  298. Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Wernecke M, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014. J Infect Dis. 2017 Feb 15;215(4):510-7.
  299. Fluad [Package Insert]. Holly Springs, NC: Seqirus; 2019.
  300. Clinical Reivew: Fluad. 24 November 2014. Silver Spring, MD: U.S. Food and Drug Administration.
  301. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013 Dec 9;31(51):6122-8.
  302. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol. 2012 Sep 15;176(6):527-33.
  303. Spadea A, Unim B, Colamesta V, Meneghini A, D'Amici AM, Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine. 2014 Sep 15;32(41):5290-4.
  304. Summary Basis for Regulatory Action: Flublok Quadrivalent. Silver Spring, MD: U.S. Food and Drug Administration; 2016.
  305. Summary Basis for Regulatory Action: FluMist. May 26,2011. Silver Spring, Maryland: U.S. Food and Drug Administration.
  306. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011 Sep 15;204(6):845-53.
  307. Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2004 Sep;23(9):852-6.
  308. Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu CY, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J. 2001 Aug;20(8):740-6.
  309. Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine. 2003 Mar 7;21(11-12):1224-31.
  310. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012 Jul;31(7):745-51.
  311. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011 Nov 21;29(50):9391-7.
  312. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14;338(20):1405-12.
  313. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb;136(2):168-75.
  314. Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009 May;28(5):365-71.
  315. Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006 Dec;118(6):2298-312.
  316. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007 Jul;26(7):619-28.
  317. Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan;158(1):65-73.
  318. Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J. 2011 Mar;30(3):203-7.
  319. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999 Jul 14;282(2):137-44.
  320. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009 Sep 24;361(13):1260-7.
  321. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22.
  322. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008 Aug 1;198(3):312-7.
  323. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses. 2011 Mar;5(2):67-75.
  324. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999 Dec 10;18(9-10):899-906.
  325. Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009 Mar 4;301(9):945-53.
  326. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine. 2009 Jun 2;27(27):3568-75.
  327. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006 Oct;25(10):870-9.
  328. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007 Feb 15;356(7):685-96.
  329. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006 Oct;25(10):860-9.
  330. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep;120(3):e553-64.
  331. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Aug 15;63(32):691-7.
  332.  CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe de la reunión: 29-30 de octubre del 2014 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE.UU., Centros para el Control y la Prevención de Enfermedades, 2014.
  333. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15;213(10):1546-56.
  334. Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016 Jan 2;34(1):77-82.
  335. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, et al. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics. 2016 Feb;137(2):e20153279.
  336. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, et al. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 15 de diciembre del 2016;63(12):1564-73.
  337. McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M, Belongia EA, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine. 2017 May 9;35(20):2685-93.
  338. CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 26 de febrero del 2015 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2015.
  339. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25.
  340. Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog. 2014 Jan;10(1):e1003831.
  341. Caspard H, Coelingh KL, Mallory RM, Ambrose CS. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. Vaccine. 2016 Sep 30;34(42):5066-72.
  342. FluMist Quadrivalent [instrucciones de empleo]. Gaithersburg, MD: MedImmune. 2015.
  343.  CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Summary report: June 22-23, 2016(Meeting Minutes). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE.UU., Centros para el Control y la Prevención de Enfermedades, 2016.
  344. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep. 2016 Aug 26;65(5):1-54.
  345. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. MMWR Recomm Rep. 2017 Aug 25;66(2):1-20.
  346. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016 Sep 22;21(38).
  347. Nohynek H, Baum U, Syrjanen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016 Sep 22;21(38).
  348. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season. J Infect Dis. 2015 Sep 1;212(5):726-39.
  349. Loeb M, Russell ML, Manning V, Fonseca K, Earn DJ, Horsman G, et al. Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial. Ann Intern Med. 2016 Nov 1;165(9):617-24.
  350. Buchan SA, Booth S, Scott AN, Simmonds KA, Svenson LW, Drews SJ, et al. Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study. JAMA Pediatr. 2018 Sep 1;172(9):e181514.
  351. National Advisory Committee on Immunization. Advisory Commitee Statement. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017.Addensum: LAIV Use Children and Adolescents. Public Health Agency of Canada; 2016.
  352.  CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 22-23 de febrero del 2017 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE.UU., Centros para el Control y la Prevención de Enfermedades, 2017.
  353.  CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe de la reunión: 25-26 de octubre del 2017 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE.UU., Centros para el Control y la Prevención de Enfermedades, 2017.
  354. Ambrose CS, Bright H, Mallory R. Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro Surveill. 2016 Nov 10;21(45).
  355. CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 21-22 de febrero del 2018 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2018.
  356. Ochiai H, Shibata M, Kamimura K, Niwayama S. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. Microbiol Immunol. 1986;30(11):1141-9.
  357. Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine. 1996 Aug;14(12):1108-10.
  358. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine. 2010 May 21;28(23):3929-35.
  359. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. J Infect Dis. 2015 Dec 15;212(12):1914-22.
  360. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008 Feb 15;197(4):490-502.
  361. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015 Jan 1;33(1):246-51.
  362. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013 Jan 31;18(5).
  363. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013 Jan 31;18(5).
  364. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013 Jan 31;18(5).
  365. Petrie JG, Ohmit SE, Truscon R, Johnson E, Braun TM, Levine MZ, et al. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. J Infect Dis. 2016 Oct 15;214(8):1142-9.
  366. Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, Lopez-Labrador FX, Librero-Lopez J, Diez-Domingo J, et al. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine. 2017 Oct 13;35(43):5799-807.
  367. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014. Vaccine. 2016 Jul 19;34(33):3907-12.
  368. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016 Apr 21;21(16).
  369. Gherasim A, Pozo F, de Mateo S, Gamarra IA, Garcia-Cenoz M, Vega T, et al. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. Vaccine. 2016 Apr 29;34(20):2371-7.
  370. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada. J Infect Dis. 2017 Dec 19;216(12):1487-500.
  371. Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis. 2017 Mar 1;64(5):544-50.
  372. Ray GT, Lewis N, Klein NP, Daley MF, Wang SV, Kulldorff M, et al. Intra-season Waning of Influenza Vaccine Effectiveness. Clin Infect Dis. 2018 Sep 10.
  373. Newall AT, Chen C, Wood JG, Stockwell MS. Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States. Vaccine. 2018 Sep 18;36(39):5910-5.
  374. Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine protection: Exploring the trade-offs of changes in vaccination timing among older adults. Clin Infect Dis. 2019 Jun 29.
  375. Hoskins TW, Davies JR, Allchin A, Miller CL, Pollock TM. Controlled trial of inactivated influenza vaccine containing the A-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain. Lancet. 1973 Jul 21;2(7821):116-20.
  376. Hoskins TW, Davies JR, Smith AJ, Allchin A, Miller CL, Pollock TM. Influenza at Christ's Hospital: March, 1974. Lancet. 1976 Jan 17;1(7951):105-8.
  377. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet. 1979 Jan 6;1(8106):33-5.
  378. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017 Jul;16(7):1-14.
  379. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul;15(10):1114-22.
  380. Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, et al. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. J Infect Dis. 2016 Apr 15;213(8):1229-36.
  381. Cheng AC, Macartney KK, Waterer GW, Kotsimbos T, Kelly PM, Blyth CC, et al. Repeated Vaccination Does Not Appear to Impact Upon Influenza Vaccine Effectiveness Against Hospitalization With Confirmed Influenza. Clin Infect Dis. 1 de enero del 2017;64(11):1564-72.
  382. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013 May;56(10):1363-9.
  383. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014 Nov 15;59(10):1375-85.
  384. Martinez-Baz I, Casado I, Navascues A, Diaz-Gonzalez J, Aguinaga A, Barrado L, et al. Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. J Infect Dis. 2017 Mar 15;215(6):847-55.
  385. Nichols MK, Andrew MK, Ye L, Hatchette TF, Ambrose A, Boivin G, et al. The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness (VE) to Prevent Influenza-Related Hospitalizations over Four Influenza Seasons in Canada. Clin Infect Dis. 2018 Dec 3.
  386. Ortqvist A, Brytting M, Leval A, Hergens MP. Impact of repeated influenza vaccinations in persons over 65years of age: A large population-based cohort study of severe influenza over six consecutive seasons, 2011/12-2016/17. Vaccine. 2018 Sep 5;36(37):5556-64.
  387. Caspard H, Heikkinen T, Belshe RB, Ambrose CS. A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children. Hum Vaccin Immunother. 2016 Jul 2;12(7):1721-7.
  388. Ramsay LC, Buchan SA, Stirling RG, Cowling BJ, Feng S, Kwong JC, et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019 Jan 10;17(1):9.
  389. Bartoszko JJ, McNamara IF, Aras OAZ, Hylton DA, Zhang YB, Malhotra D, et al. Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis. Vaccine. 2018 Jun 7;36(24):3434-44.
  390. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004 Nov;158(11):1031-6.
  391. Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006 Oct 25;296(16):1990-7.
  392. Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu S, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug;165(8):749-55.
  393. Barry DW, Mayner RE, Hochstein HD, Dunlap RC, Rastogi SC, Hannah JE, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol. 1976 Jul;104(1):47-59.
  394. Stockwell MS, Broder KR, Lewis P, Jakob K, Iqbal S, Fernandez N, et al. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination. J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e7-e14.
  395. Walter EB, Hornik CP, Grohskopf L, McGee CE, Todd CA, Museru OI, et al. The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. Vaccine. 2017 Dec 4;35(48 Pt B):6664-71.
  396. Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial. J Pediatric Infect Dis Soc. 2016 Jun;5(2):170-9.
  397. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015. Vaccine. 2016 May 11;34(22):2507-12.
  398. Steering Committee on Quality, Improvement, Management, Subcommittee on Febrile Seizures American Academy of Pediatrics. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008 Jun;121(6):1281-6.
  399. Francis JR, Richmond P, Robins C, Lindsay K, Levy A, Effler PV, et al. An observational study of febrile seizures: the importance of viral infection and immunization. BMC Pediatr. 2016 Dec 3;16(1):202.
  400. Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, Weintraub ES, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010 Jan 15;171(2):177-88.
  401. Australian Government Department of Health and Ageing-Therapeitic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination. 2010.
  402. CDC. Actualización: recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP) relacionadas con el uso de la vacuna contra la influenza estacional (Afluria) de CSL en los Estados Unidos durante 2010-11. Informe Semanal de Morbilidad y Mortalidad (MMWR) 2010 ago. 13;59(31):989-92.
  403. Rockman S, Dyson A, Koernig S, Becher D, Ng M, Morelli AB, et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events. Vaccine. 2014 Jun 24;32(30):3861-8.
  404. Rockman S, Becher D, Dyson A, Koernig S, Morelli AB, Barnden M, et al. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine. 2014 Jun 24;32(30):3869-76.
  405. Sawlwin DC, Graves Jones A, Albano FR. Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children. Vaccine. 2019 Apr 24;37(18):2447-54.
  406. European Clinical Trials Register. Clinical Trial Results: A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL's Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years of Age. Eudra CT Number 2015-000175-27.
  407. Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine. 2017 May 9;35(20):2745-52.
  408. Summary Basis fro Regulatory Action: Afluria Quadrivalent. 3 October 2018. Silver Spring, MD: U.S. Food and Drug Administration.
  409. Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59months of age: A phase 3, randomized, noninferiority study. Vaccine. 2019 Jan 7;37(2):343-51.
  410. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine. 2012 Mar 2;30(11):2020-3.
  411. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012 Mar 2;30(11):2024-31.
  412. CDC. Prevención y control de la influenza con vacunas: recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP), 2011. Informe Semanal de Morbilidad y Mortalidad (MMWR), 26 de agosto del 2011;60(33):1128-32.
  413. CDC. Recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP) para la prevención de la enfermedad neumocócica entre bebés y niños (uso de la vacuna vacuna conjugadas neumocócicas 13-valente y la vacuna neumocócica polisacárida 23-valente). Informe Semanal de Morbilidad y Mortalidad (MMWR), 10 de diciembre del 2010;59(RR-11):1-18.
  414. Duffy J, Weintraub E, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, et al. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics. 2016 Jul;138(1).
  415. Kawai AT, Martin D, Kulldorff M, Li L, Cole DV, McMahill-Walraven CN, et al. Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine. Pediatrics. 2015 Oct;136(4):e848-55.
  416. Stockwell MS, Broder K, LaRussa P, Lewis P, Fernandez N, Sharma D, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr. 2014 Mar;168(3):211-9.
  417. Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):928-34.
  418. Yih WK, Kulldorff M, Sandhu SK, Zichittella L, Maro JC, Cole DV, et al. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Pharmacoepidemiol Drug Saf. 2016 May;25(5):481-92.
  419. Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J Pediatr. 1976 Jan;88(1):31-5.
  420. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SH, Karzon DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis. 1977 Dec;136 Suppl:S731-41.
  421. Wright PF, Dolin R, La Montagne JR. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines-II. J Infect Dis. 1976 Dec;134(6):633-8.
  422. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J Infect Dis. 1977 Dec;136 Suppl:S616-25.
  423. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics. 1982 Apr;69(4):404-8.
  424. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics. 1991 Jun;87(6):823-8.
  425. Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, et al. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. J Pediatric Infect Dis Soc. 2015 Sep;4(3):214-24.
  426. Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O, Rodriguez-Weber MA, Leonardi ML, et al. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):9-19.
  427. Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial. Pediatr Infect Dis J. 2019 Mar;38(3):323-8.
  428. Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ. 1993 Oct 16;307(6910):988-90.
  429. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA. 1990 Sep 5;264(9):1139-41.
  430. Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge M, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med. 1996 Jul 22;156(14):1546-50.
  431. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009 Mar 26;27(15):2114-20.
  432. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Code of Federal Regulations.2010;Title 21(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=600/80).
  433. Vickers ER, McClure DL, Naleway AL, Jacobsen SJ, Klein NP, Glanz JM, et al. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine. 2017 Oct 13;35(43):5872-7.
  434. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013 Jan 30;31(6):861-6.
  435. Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Clin Infect Dis. 2012 Jun;54(11):1608-14.
  436. Kaka AS, Filice GA, Myllenbeck S, Nichol KL. Comparison of Side Effects of the 2015-2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults >/=65 Years. Open Forum Infect Dis. 2017 Winter;4(1):ofx001.
  437. Haber P, Moro PL, Ng C, Dores GM, Lewis P, Cano M. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018. Vaccine. 2019 Mar 7;37(11):1516-20.
  438. Jain VK, Chandrasekaran V, Wang L, Li P, Liu A, Innis BL. A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine. BMC Infect Dis. 2014 Mar 10;14:133.
  439. Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax((R))) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015. Vaccine. 2015 Nov 27;33(48):6684-8.
  440. Clinical Review: Flucelvax Quadrivalent, 20 May 2016. Silver Spring, MD: U.S. Food and Drug Administration. .
  441. Daubeney P, Taylor CJ, McGaw J, Brown EM, Ghosal S, Keeton BR, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin Pract. 1997 Mar;51(2):87-90.
  442. Berry BB, Ehlert DA, Battiola RJ, Sedmak G. Influenza vaccination is safe and immunogenic when administered to hospitalized patients. Vaccine. 2001 May 14;19(25-26):3493-8.
  443. Wongsurakiat P, Maranetra KN, Gulprasutdilog P, Aksornint M, Srilum W, Ruengjam C, et al. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. Respirology. 2004 Nov;9(4):550-6.
  444. Patria MF, Tenconi R, Esposito S. Efficacy and safety of influenza vaccination in children with asthma. Expert Rev Vaccines. 2012 Apr;11(4):461-8.
  445. Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, Wiselka MJ, Leese J, Ayres J, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet. 1998 Jan 31;351(9099):326-31.
  446. Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. J Asthma. 2007 Dec;44(10):817-22.
  447. Seo YB, Baek JH, Lee J, Song JY, Lee JS, Cheong HJ, et al. Long-Term Immunogenicity and Safety of a Conventional Influenza Vaccine in Patients with Type 2 Diabetes. Clin Vaccine Immunol. 2015 Nov;22(11):1160-5.
  448. Ho DD. HIV-1 viraemia and influenza. Lancet. 1992 Jun 20;339(8808):1549.
  449. Amendola A, Boschini A, Colzani D, Anselmi G, Oltolina A, Zucconi R, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001 Dec;65(4):644-8.
  450. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis. 1999 Mar;28(3):541-7.
  451. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis. 1996 Dec;174(6):1332-6.
  452. Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW, Adult, et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS. 2000 Dec 1;14(17):2781-5.
  453. Fowke KR, D'Amico R, Chernoff DN, Pottage JC, Jr., Benson CA, Sha BE, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997 Jul;11(8):1013-21.
  454. Couch RB. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis. 1999 Mar;28(3):548-51.
  455. Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000 Feb;181(2):522-31.
  456. Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010 Apr 15;89(7):838-44.
  457. Dos Santos G, Haguinet F, Cohet C, Webb D, Logie J, Ferreira GL, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series. Vaccine. 2016 Jun 30;34(31):3598-606.
  458. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant. 1999 Mar;18(3):220-5.
  459. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 2001 Apr;7(4):311-3.
  460. Suzuki M, Torii Y, Kawada J, Kimura H, Kamei H, Onishi Y, et al. Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons. Microbiol Immunol. 2013 Oct;57(10):715-22.
  461. Moon JS, Souayah N. Guillain-Barre syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506. Liver Transpl. 2006 Oct;12(10):1537-9.
  462. Raman KS, Chandrasekar T, Reeve RS, Roberts ME, Kalra PA. Influenza vaccine-induced rhabdomyolysis leading to acute renal transplant dysfunction. Nephrol Dial Transplant. 2006 Feb;21(2):530-1.
  463. Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization. Am J Ophthalmol. 1988 Nov 15;106(5):575-8.
  464. Solomon A, Frucht-Pery J. Bilateral simultaneous corneal graft rejection after influenza vaccination. Am J Ophthalmol. 1996 Jun;121(6):708-9.
  465. Wertheim MS, Keel M, Cook SD, Tole DM. Corneal transplant rejection following influenza vaccination. Br J Ophthalmol. 2006 Jul;90(7):925.
  466. Hamilton A, Massera R, Maloof A. Stromal rejection in a deep anterior lamellar keratoplasty following influenza vaccination. Clin Exp Ophthalmol. 2015 Dec;43(9):838-9.
  467. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis Rheumatol. 2017 Apr;69(4):687-99.
  468. Laubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018 May 22;6(1):40.
  469. Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018 Nov;104:182-7.
  470. Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2019 Feb 22;7(1):53.
  471. Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI). Clin Infect Dis. 2019 Mar 15.
  472. Ropper AH. The Guillain-Barre syndrome. N Engl J Med. 1992 Apr 23;326(17):1130-6.
  473. Kalra V, Chaudhry R, Dua T, Dhawan B, Sahu JK, Mridula B. Association of Campylobacter jejuni infection with childhood Guillain-Barre syndrome: a case-control study. J Child Neurol. 2009 Jun;24(6):664-8.
  474. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998 Oct;51(4):1110-5.
  475. Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology. 1998 Aug;51(2):371-8.
  476. Wachira VK, Peixoto HM, de Oliveira MRF. Systematic review of factors associated with the development of Guillain-Barre syndrome 2007-2017: what has changed? Trop Med Int Health. 2019 Feb;24(2):132-42.
  477. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis. 2009 Jan 1;48(1):48-56.
  478. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979 Aug;110(2):105-23.
  479. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain-Barre syndrome following influenza vaccination. JAMA. 2004 Nov 24;292(20):2478-81.
  480. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998 Dec 17;339(25):1797-802.
  481. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barre syndrome and the 1978-1979 influenza vaccine. N Engl J Med. 1981 Jun 25;304(26):1557-61.
  482. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA. 1982 Aug 13;248(6):698-700.
  483. Chen R, Kent J, Rhodes P, al. e. Investigations of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990-1991 [Abstract 040]. Post MarketingSurveillance. 1992;6:5-6.
  484. CDC. Seguridad de las vacunas monovalentes contra la influenza A (H1N1) 2009 -- Estados Unidos, del 1 de octubre al 24 de noviembre del 2009 Informe Semanal de Morbilidad y Mortalidad MMWR, 11 de diciembre del 2009;58(48):1351-6.
  485. Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, Morgan O, et al. The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf. 2012 May;21(5):546-52.
  486. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, et al. Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol. 2012 Jun 1;175(11):1110-9.
  487. Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol. 2012 Jun 1;175(11):1100-9.
  488. Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, Rett M, et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol. 2012 Jun 1;175(11):1120-8.
  489. Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia B, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health. 2012 Oct;102(10):1921-7.
  490. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013 Apr 27;381(9876):1461-8.
  491. Polakowski LL, Sandhu SK, Martin DB, Ball R, Macurdy TE, Franks RL, et al. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol. 2013 Sep 15;178(6):962-73.
  492. Sandhu SK, Hua W, MaCurdy TE, Franks RL, Avagyan A, Kelman J, et al. Near real-time surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14. Vaccine. 2017 May 19;35(22):2986-92.
  493. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014 Apr;58(8):1149-55.
  494. Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP, Network C. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis. 2012 Mar;54(6):800-4.
  495. CDC. Resumen de la declaración conjunta sobre el timerosal en las vacunas. American Academy of Family Physicians, American Academy of Pediatrics, Comité Asesor sobre Prácticas de Vacunación, Servicios de Salud Pública. Informe Semanal de Morbilidad y Mortalidad (MMWR), 14 de julio del 2000;49(27):622-31.
  496. Stratton K, Gable, A., McCormick, M.C. Report of the Institute of Medicine. Immunization safety review: thimerosal containing vaccines and neurodevelopmental disorders. In: Stratton K, McCormick, M.C., editor. Washington, DC: National Academy Press; 2001.
  497. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet. 2002 Nov 30;360(9347):1737-41.
  498. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003 Nov;112(5):1039-48.
  499. McCormick M, Bayer, R., Berg A., et al. Report of the Institute of Medicine. Immunization safety review: vaccines and autism. Washington, DC: Institute of Medicine; 2004.
  500. Pichichero ME, Gentile A, Giglio N, Umido V, Clarkson T, Cernichiari E, et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics. 2008 Feb;121(2):e208-14.
  501. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry. 2008 Jan;65(1):19-24.
  502. Croen LA, Matevia M, Yoshida CK, Grether JK. Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders. Am J Obstet Gynecol. 2008 Sep;199(3):234 e1-6.
  503. Tozzi AE, Bisiacchi P, Tarantino V, De Mei B, D'Elia L, Chiarotti F, et al. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines. Pediatrics. 2009 Feb;123(2):475-82.
  504. Price CS, Thompson WW, Goodson B, Weintraub ES, Croen LA, Hinrichsen VL, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010 Oct;126(4):656-64.
  505. Pichichero ME, Gentile A, Giglio N, Alonso MM, Fernandez Mentaberri MV, Zareba G, et al. Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. J Pediatr. 2009 Oct;155(4):495-9.
  506. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007 Sep 27;357(13):1281-92.
  507. Barile JP, Kuperminc GP, Weintraub ES, Mink JW, Thompson WW. Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later. J Pediatr Psychol. 2012 Jan-Feb;37(1):106-18.
  508. Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016 Feb 3;34(6):714-22.
  509. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Med Rev. 2018 Apr;38:177-86.
  510. Verstraeten T, Cohet C, Dos Santos G, Ferreira GL, Bollaerts K, Bauchau V, et al. Pandemrix and narcolepsy: A critical appraisal of the observational studies. Hum Vaccin Immunother. 2016;12(1):187-93.
  511. Wijnans L, Dodd C, de Ridder M, Romio S, Weibel D, Overeem S, et al. Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. Expert Rev Vaccines. 2016 May;15(5):573-84.
  512. Sturkenboom MC. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine. 2015 Jun 8;33 Suppl 2:B6-B13.
  513. Bollaerts K, Shinde V, Dos Santos G, Ferreira G, Bauchau V, Cohet C, et al. Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix and Narcolepsy. PLoS One. 2016;11(2):e0149289.
  514. Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, et al. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment. Vaccine. 2018 Oct 1;36(41):6202-11.
  515. Choe YJ, Bae GR, Lee DH. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study. Vaccine. 2012 Dec 14;30(52):7439-42.
  516. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS). Supplementary statement on influenza vaccination: continued use of Fluviral influenza vaccine in the 2000-2001 season. Can Commun Dis Rep. 2001 Jan 15;27:1-3.
  517. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS). Supplementary Statement for the 2001-2002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenzavaccination. Can Commun Dis Rep. 2001 Nov 15;27:1-7.
  518. De Serres G, Toth E, Menard S, Grenier JL, Roussel R, Tremblay M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine. 2005 May 25;23(28):3726-32.
  519. Skowronski DM, De Serres G, Hebert J, Stark D, Warrington R, Macnabb J, et al. Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine. 2002 Jun 21;20(21-22):2713-9.
  520. Woo EJ, Moro PL, Cano M, Jankosky C. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Vaccine. 2017 Oct 9;35(42):5618-21.
  521. Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, et al. Randomized comparison of the safety of Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults >/= 50 years of age. Vaccine. 2015 Nov 27;33(48):6622-8.
  522. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008 Sep 8;26(38):4940-6.
  523. Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine. 2011 Jun 10;29(26):4322-7.
  524. King JC, Jr., Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000 Feb;181(2):725-8.
  525. King JC, Jr., Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001 Dec;20(12):1124-31.
  526. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpaa R, Salmi A, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006 Jul;25(7):590-5.
  527. Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol. 2000 Feb;38(2):839-45.
  528. Zhou B, Meliopoulos VA, Wang W, Lin X, Stucker KM, Halpin RA, et al. Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus. J Virol. 2016 Oct 1;90(19):8454-63.
  529. Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis. 2004 Oct 1;39(7):920-7.
  530. Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004 Feb;23(2):138-44.
  531. King JC, Jr., Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis. 1998 May;177(5):1394-7.
  532. Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002 Jan;21(1):44-8.
  533. Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002 Oct;110(4):662-72.
  534. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine. 2008 Sep 12;26 Suppl 4:D10-6.
  535. Baxter RP, Lewis N, Fireman B, Hansen J, Klein NP, Ortiz JR. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. Pediatr Infect Dis J. 2018 May;37(5):383-6.
  536. Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep;116(3):e397-407.
  537. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May;27(5):444-52.
  538. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005 Dec 7;294(21):2720-5.
  539. Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, et al. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012. J Pediatric Infect Dis Soc. 2015 Sep;4(3):205-13.
  540. Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, et al. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):59-68.
  541. Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. Vaccine. 2015 Apr 15;33(16):1987-92.
  542. Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years. Vaccine. 2017 Mar 1;35(9):1254-8.
  543. Mallory RM, Yu J, Kameo S, Tanaka M, Rito K, Itoh Y, et al. The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies. Influenza Other Respir Viruses. 2018 Mar 23.
  544. Caspard H, Steffey A, Mallory RM, Ambrose CS. Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink. BMJ Open. 2018 Dec 9;8(12):e023118.
  545. Curtis D, Ning MF, Armon C, Li S, Weinberg A. Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children. Vaccine. 2015 Sep 11;33(38):4790-7.
  546. Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2549-57.
  547. Ray GT, Lewis N, Goddard K, Ross P, Duffy J, DeStefano F, et al. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017 May 9;35(20):2668-75.
  548. Duffy J, Lewis M, Harrington T, Baxter R, Belongia EA, Jackson LA, et al. Live attenuated influenza vaccine use and safety in children and adults with asthma. Ann Allergy Asthma Immunol. 2017 Apr;118(4):439-44.
  549. Boikos C, Joseph L, Scheifele D, Lands LC, De Serres G, Papenburg J, et al. Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine. 2017 Sep 5;35(37):5019-26.
  550. Getahun D, Fassett MJ, Peltier MR, Takhar HS, Shaw SF, Im TM, et al. Association between seasonal influenza vaccination with pre- and postnatal outcomes. Vaccine. 2019 Mar 22;37(13):1785-91.
  551. Sheffield JS, Greer LG, Rogers VL, Roberts SW, Lytle H, McIntire DD, et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol. 2012 Sep;120(3):532-7.
  552. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine. 2015 Apr 27;33(18):2108-17.
  553. Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009 Dec 19;374(9707):2115-22.
  554. Chambers CD, Johnson DL, Xu R, Luo YJ, Louik C, Mitchell AA, et al. Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine. 2016 Aug 17;34(37):4443-9.
  555. Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine. 2014 Nov 12;32(48):6463-8.
  556. Ma F, Zhang L, Jiang R, Zhang J, Wang H, Gao X, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol. 2014 Sep;21(9):1282-7.
  557. Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J, DeStefano F, et al. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol. 2013 Jan;121(1):159-65.
  558. Chambers CD, Johnson D, Xu R, Luo Y, Louik C, Mitchell AA, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine. 2013 Oct 17;31(44):5026-32.
  559. Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine. 2012 Jun 22;30(30):4445-52.
  560. Pasternak B, Svanstrom H, Molgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ. 2012 May 2;344:e2794.
  561. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One. 2012 Dec 20;7(12):e51734.
  562. Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol. 2012 Sep;207(3):177 e1-8.
  563. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis. 2015 Mar 1;60(5):e11-9.
  564. Giles ML, Krishnaswamy S, Macartney K, Cheng A. The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review. Hum Vaccin Immunother. 2018 Oct 31:1-13.
  565. Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis. 2008 Jan;8(1):44-52.
  566. Moro PL, Tepper NK, Grohskopf LA, Vellozzi C, Broder K. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. Expert Rev Vaccines. 2012 Aug;11(8):911-21.
  567. Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine. 2017 Sep 25;35(40):5314-22.
  568. CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 27-28 de febrero del 2019 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2019.
  569. Regan AK, Moore HC, de Klerk N, Omer SB, Shellam G, Mak DB, et al. Seasonal Trivalent Influenza Vaccination During Pregnancy and the Incidence of Stillbirth: Population-Based Retrospective Cohort Study. Clin Infect Dis. 2016 May 15;62(10):1221-7.
  570. Ludvigsson JF, Strom P, Lundholm C, Cnattingius S, Ekbom A, Ortqvist A, et al. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ. 2015 Nov 16;351:h5585.
  571. Baum U, Leino T, Gissler M, Kilpi T, Jokinen J. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination. Vaccine. 2015 Sep 11;33(38):4850-7.
  572. Wortman AC, Casey BM, McIntire DD, Sheffield JS. Association of influenza vaccination on decreased stillbirth rate. Am J Perinatol. 2015 May;32(6):571-6.
  573. Fabiani M, Bella A, Rota MC, Clagnan E, Gallo T, D’Amato M, et al. A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine. 2015 May 5;33(19):2240-7.
  574. Fell DB, Sprague AE, Liu N, Yasseen AS, 3rd, Wen SW, Smith G, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. Am J Public Health. 2012 Jun;102(6):e33-40.
  575. Munoz FM, Greisinger AJ, Wehmanen OA, Mouzoon ME, Hoyle JC, Smith FA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2005 Apr;192(4):1098-106.
  576. Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland A, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol. 2011 Feb;204(2):146 e1-7.
  577. Moro P, Baumblatt J, Lewis P, Cragan J, Tepper N, Cano M. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016. Drug Saf. 2017 Feb;40(2):145-52.
  578. Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, et al. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. J Pediatr. 2017 Aug;187:234-9 e4.
  579. Louik C, Kerr S, Van Bennekom CM, Chambers C, Jones KL, Schatz M, et al. Safety of the 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: Preterm delivery and specific malformations, a study from the case-control arm of VAMPSS. Vaccine. 2016 Aug 17;34(37):4450-9.
  580. Ludvigsson JF, Strom P, Lundholm C, Cnattingius S, Ekbom A, Ortqvist A, et al. Risk for Congenital Malformation With H1N1 Influenza Vaccine: A Cohort Study With Sibling Analysis. Ann Intern Med. 2016 Dec 20;165(12):848-55.
  581. Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Nov;126(5):1075-84.
  582. Louik C, Ahrens K, Kerr S, Pyo J, Chambers C, Jones KL, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. Vaccine. 2013 Oct 17;31(44):5033-40.
  583. Conlin AMS, Bukowinski AT, Levine JA, Khodr ZG, Kaur N, Farrish SC, et al. A follow-up comparative safety analysis of pandemic H1N1 vaccination during pregnancy and risk of infant birth defects among U.S. military mothers. Vaccine. 2018 May 11;36(20):2855-60.
  584. Omer SB, Goodman D, Steinhoff MC, Rochat R, Klugman KP, Stoll BJ, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med. 2011 May;8(5):e1000441.
  585. Richards JL, Hansen C, Bredfeldt C, Bednarczyk RA, Steinhoff MC, Adjaye-Gbewonyo D, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin Infect Dis. 2013 May;56(9):1216-22.
  586. Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H, Vellozzi C, Destefano F, et al. Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr. 2014 May;164(5):1051-7 e2.
  587. Dodds L, MacDonald N, Scott J, Spencer A, Allen VM, McNeil S. The association between influenza vaccine in pregnancy and adverse neonatal outcomes. J Obstet Gynaecol Can. 2012 Aug;34(8):714-20.
  588. Zerbo O, Modaressi S, Chan B, Goddard K, Lewis N, Bok K, et al. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 May 31;35(24):3186-90.
  589. Fell DB, Platt RW, Lanes A, Wilson K, Kaufman JS, Basso O, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG. 2015 Jan;122(1):17-26.
  590. McHugh L, Marshall HS, Perrett KP, Nolan T, Wood N, Lambert SB, et al. The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012-2015: The FluMum Study. Clin Infect Dis. 2019 Jan 18;68(3):402-8.
  591. Vazquez-Benitez G, Kharbanda EO, Naleway AL, Lipkind H, Sukumaran L, McCarthy NL, et al. Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies. Am J Epidemiol. 2016 Aug 1;184(3):176-86.
  592. Zerbo O, Qian Y, Yoshida C, Fireman BH, Klein NP, Croen LA. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan 2;171(1):e163609.
  593. Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, et al. Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics. 2018 Feb 20.
  594. Clinical Review, January 16, 2013-Flublok. U.S. Department of Health and Human Services, Foodand Drug Administration; 2013.
  595. Toback SL, Beigi R, Tennis P, Sifakis F, Calingaert B, Ambrose CS. Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza Other Respir Viruses. 2012 Jan;6(1):44-51.
  596. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008 Sep;122(3):e771-7.
  597. Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 1;25(31):5675-84.
  598. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). [www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/downloads/general-recs.pdf]. Accessed 29 May 2019. .
  599. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. J Allergy Clin Immunol. 2019 Jan 14.
  600. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar;137(3):868-78.
  601. CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 19-20 de junio del 2013 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2013.
  602. CDC. Comité Asesor sobre Prácticas de Vacunación (ACIP). Informe del resumen: 20-21 de junio del 2012 (Actas de la reunión). Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2012.
  603. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003 Oct;112(4):815-20.
  604. Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol. 2012 Nov;130(5):1213-6 e1.
  605. Des Roches A, Samaan K, Graham F, Lacombe-Barrios J, Paradis J, Paradis L, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):138-9.
  606. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Investigators SS. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015 Aug;136(2):376-81.
  607. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Investigators S-S. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. 2015 Dec 8;351:h6291.
  608. Turner PJ, Erlewyn-Lajeunesse M. Intranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):312-3.

Páginas en este informe

  1. Antecedentes y epidemiología
  2. Inmunogenia, eficacia y efectividad de las vacunas contra la influenza
  3. Seguridad de las vacunas contra la influenza
  4. ›Referencias
  5. Enlaces a directrices actuales y anteriores
  6. Tabla

Descargo de responsabilidad: Es posible que en este sitio encuentre algunos enlaces que le lleven a contenido disponible sólo en inglés. Además, el contenido que se ha traducido del inglés se actualiza a menudo, lo cual puede causar la aparición temporal de algunas partes en ese idioma hasta que se termine de traducir (generalmente en 24 horas). Llame al 1-800-CDC-INFO si tiene preguntas sobre la influenza estacional, cuyas respuestas no ha encontrado en este sitio. Agradecemos su paciencia.